Drug intelligence / Profile preview

TSB-IL23A

Development stage: Preclinical
Lead developer: TargetSite Therapeutics
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Oral, Endoscopic

Overview

TSB-IL23A is a preclinical-stage oligonucleotide therapeutic being developed by TargetSite Therapeutics, a Yale University spinout. The drug utilizes the company's proprietary TargetSite Blocker (TSB) platform, which employs a novel mechanism of action to modulate gene expression. Specifically, TSB-IL23A is designed to inhibit or stabilize the interaction between microRNAs (miRNAs) and the messenger RNA (mRNA) of Interleukin-23 subunit alpha (IL-23A). By interfering with these unconventional miRNA-mediated mRNA stabilization pathways, the drug modulates the stability of IL23A mRNA, leading to a reduction in the expression of the pro-inflammatory cytokine IL-23A. This therapeutic approach is aimed at treating chronic inflammatory and autoimmune diseases where the IL-23 pathway is a validated driver of pathology.

Other names: TargetSite Blocker - IL23A inhibitorIL23A TargetSite BlockerIL-23A TargetSite BlockerIL 23A TargetSite Blocker

Targets

IL23A (Interleukin-23 p19 Subunit)

Beyond the preview

Go deeper on TSB-IL23A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSB-IL23A.

Explore the full profile